These pathways, molecules or niche-related factors that are independent of BCR–ABL contribute to the proliferation and survival of leukemic stem cells in CML, thereby promoting drug resistance (24, 25). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.